109
Participants
Start Date
October 1, 2018
Primary Completion Date
November 22, 2023
Study Completion Date
December 14, 2023
TAK-981
Intravenous infusion.
Fox Chase Cancer Center, Philadelphia
University Hospitals Seidman Cancer Center, Cleveland
Barbara Ann Karmanos Cancer Institute, Detroit
Froedtert and the Medical College of Wisconsin, Milwaukee
HealthPartners Cancer Care Center - Regions Hospital, Saint Paul
The University of Texas MD Anderson Cancer Center, Houston
University of California San Diego Moores Cancer Center, La Jolla
Massachusetts General Hospital, Boston
Lead Sponsor
Takeda
INDUSTRY